Abbott Laboratories (ABT) Stock Analysis
$ABT · Healthcare · Medical - Devices · NYSE
Abbott Laboratories (ABT), a Medical - Devices company, is listed on NYSE, has a market capitalization of about $181.48B and trades at 35.3x trailing earnings.
Price
$104.88
Market cap
$181.48B
P/E ratio
35.3x
Dividend yield
2.36%
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vacci
How StockWorthy values ABT
StockWorthy forecasts Abbott Laboratories's revenue, operating profitability, reinvestment (capital expenditure, depreciation and working capital) and unlevered free cash flow, then discounts those cash flows using a normalized cost of capital built from ABT's size, profitability and balance-sheet risk. Terminal growth is adjusted to reflect the company's mature growth profile rather than a fixed number. The model presents bear, base and bull scenarios, and every key assumption stays transparent and adjustable in the full StockWorthy analysis. Results are educational and not investment advice.
See ABT's Fair Value
Create a free account to view Abbott Laboratories's base-case fair value, the bear–bull modeled range, and every assumption behind them. Free accounts include 5 stock valuations per month — plus Advanced DCF models, financial charts, dividends, and peer analysis.